Satellos Bioscience logo

Satellos Bioscience(NASDAQ) MSLE

Market Cap$152.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-67%
5 Year-54%
1 Year+4%
1 Month-26%
$7.04
-1.81%
-0.13Today
Satellos Bioscience last closing stock price
MetricPriceDate
Last closeUSD 7.172026-10-12
Satellos Bioscience stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10.93%USD 8.052026-10-05
1 month-26.46%USD 9.752026-09-11
3 month-20.38%USD 9.012026-07-14
Year to date+21.94%USD 5.882025-12-31
1 year+3.91%USD 6.902025-10-10
3 year+96.35%USD 3.652023-10-13
5 year-53.73%USD 15.492021-10-12
Since inception-67.14%USD 21.822021-08-18

Satellos Bioscience Financials at a Glance

Market Cap

$152.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$34.31M

EPS (TTM)

-$1.98

P/E Ratio

-3.62

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$7.04

Volume

92,954

Open

$7.16

Previous Close

$7.04

Daily Range

$6.88 - $7.45

52-Week Range

$5.30 - $13.39

Estimated Earnings Date

Nov 13, 2026

MSLE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Satellos Bioscience

Satellos Bioscience Inc. is a biotechnology company focused on developing innovative medicines for degenerative muscle diseases, primarily operating in Canada and Australia. Utilizing its proprietary MyoReGenX platform, the company aims to create effective treatments, including its lead candidate SAT-3247 for Duchenne muscular dystrophy.

Products and Services
  • Development of SAT-3247, an oral drug for Duchenne muscular dystrophy
  • Proprietary MyoReGenX platform for muscle stem cell research
  • Collaborative research agreements with leading institutions
Growth Outlook
  • Strong pipeline with potential for significant market impact in muscle diseases
  • Partnerships with Ottawa Hospital Research Institute and University of British Columbia
  • Increasing focus on muscle regeneration therapies in the biotechnology sector
Financial Highlights
  • Recent quarterly net income of -$11.4 million, reflecting ongoing R&D investments
  • Cash and short-term investments totaling $61.8 million as of June 30, 2026
  • Current ratio of 11.22, indicating strong liquidity position
Satellos Bioscience Inc. is positioned in a growing biotechnology sector, focusing on innovative treatments for muscle-related diseases. The company's proprietary MyoReGenX platform and strategic partnerships enhance its potential for success. Recent financial data indicates a robust liquidity position, allowing for continued investment in research and development. Despite current net losses, the focus on groundbreaking therapies may attract investor interest as the company progresses in its mission to address significant unmet medical needs.
AI Generated • Sep 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

18

CEO

Frank Gleeson, MBA

Website

www.satellos.com

Headquarters

Toronto, ON M5J 2J1, CA

MSLE Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-72.67%

Return on Capital

-95.23%

Return on Assets

-53.20%

Earnings Yield

-27.62%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$152.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

21.22M

Volume

92.95K

Avg. Volume

48.72K

Financials (TTM)

Gross Profit

-$3.97K

Operating Income

-$35.51M

EBITDA

-$35.51M

Operating Cash Flow

-$28.67M

Capital Expenditure

-$6.96K

Free Cash Flow

-$28.68M

Cash & ST Invst.

$61.76M

Total Debt

$0.00

Satellos Bioscience Performance Analysis

Satellos Bioscience annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Satellos Bioscience sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Satellos Bioscience annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.93-52.5%
20232023-12-31USD -1.64-44.1%
20242024-12-31USD -2.1431.2%
20252025-12-31USD -1.70-20.5%
Satellos Bioscience sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31-33.3%
Q12026-03-31-10.4%
Q22026-06-30-3.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$974.00

+4.2%

Gross Margin

0.00%

N/A

Market Cap

$152.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$8.45M

N/A

Employees

18

N/A

Net Income

-$11.42M

-103.6%

EBITDA

-$11.86M

-86.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$61.76M

+61.6%

Total Debt

$0.00

N/A

Accounts Receivable

$782.06K

+320.5%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-53.20%

N/A

Return on Invested Capital

-60.09%

N/A

Free Cash Flow

-$7.83M

-61.6%

Operating Cash Flow

-$7.83M

-61.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,803.85-0.00%
^DJIDJI
$51,687.96-0.00%
^IXICNASDAQ
$27,201.84-0.00%
BTCBitcoin
$83,069.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About MSLE

What is the current price of Satellos Bioscience?

Satellos Bioscience is trading at $7.04 per share.

What is the 52-week range for Satellos Bioscience?

Over the past 52 weeks, Satellos Bioscience has traded between $5.30 and $13.39.

How much debt does Satellos Bioscience have?

As of the most recent reporting period, Satellos Bioscience reported total debt of $0.00.

How much cash does Satellos Bioscience have on hand?

Satellos Bioscience reported $7.39M in cash and cash equivalents in its most recent financial results.

What is Satellos Bioscience’s dividend yield?

Satellos Bioscience does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services